NextPlat Q3 Revenue Falls to $10.5M, Net Loss Cut 66%

NextPlat Corp (NASDAQ: NXPL) reported third-quarter 2026 revenue of approximately $10.5 million, down from $13.8 million a year earlier, while net loss attributable to common stockholders narrowed roughly 66% to about $0.7 million, or $0.28 per diluted share, the company announced on November 12, 2026. Consolidated gross margin reached approximately 35.0%, against 19.9% in the prior-year quarter, and the company ended September 30 with about $11.2 million in cash and $13.5 million in working capital.

Context — why NextPlat's shrinking revenue is the point

The headline revenue decline is the deliberate result of NextPlat's healthcare mix shift, not a demand collapse. The company said lower reimbursement rates and lower retail prescription volumes pulled top-line prescription revenue down to roughly $4.3 million from about $9.5 million a year earlier, but those same factors strengthened segment gross margin.

That trade-off is the central story of the quarter. NextPlat's Healthcare Operations segment gross margin held near 41%, a 23 percentage point improvement from 18% in the third quarter of 2025. The company is effectively trading low-margin retail volume for higher-margin contracted services.

The clearest expression of that pivot is pharmacy contract revenue, which rose 300% to approximately $2.4 million from roughly $0.6 million a year earlier. Within that, 340B contract revenue contributed about $1.6 million of growth, split between roughly $1.0 million from existing contracts and $0.6 million from new ones. Medication fulfillment contract services added about $0.2 million.

340B is a US federal drug discount program that lets qualifying hospitals and clinics buy outpatient drugs at reduced prices. Serving those entities is contract work rather than counter retail, which is why the revenue carries a different margin profile.

The timing matters because the company is absorbing lower reimbursement while it rebuilds its revenue base. Management framed the quarter as evidence that the refocused healthcare model can deliver consistent bottom-line results in what it called a dynamic market.

Data — what the numbers show

NextPlat's third-quarter operating expenses fell to approximately $4.5 million from roughly $4.9 million, helped by a $0.3 million reduction in salaries, wages and payroll taxes and a $0.3 million drop in litigation settlement losses, partly offset by a $0.1 million increase in professional fees.

The operating loss narrowed to $0.8 million from $2.2 million. Nine-month revenue through September 30 came to $32.2 million versus $40.9 million a year earlier, while the nine-month net loss attributable to common stockholders fell to $2.0 million, or $0.75 per diluted share, from $5.9 million, or $2.28 per share.

The table below sets the quarter against the prior-year period.

Metric (Q3)	2026	2025
Revenue	~$10.5M	~$13.8M
Gross profit	$3.7M	$2.7M
Gross margin	~35.0%	19.9%
Operating expenses	~$4.5M	~$4.9M
Net loss to common	~$0.7M	~$2.2M
Loss per diluted share	($0.28)	($0.84)

E-commerce revenue rose 3% to approximately $3.8 million from about $3.7 million, driven by record airtime contract revenue. The company said it sold to customers in more than 115 countries during the quarter and around 150 year-to-date. E-commerce gross margin held stable near 24%.

On the balance sheet, cash fell to $11.2 million from $13.7 million at December 31, 2025, receivables rose to $7.1 million from $5.9 million, and inventory increased to $4.3 million from $3.4 million. Total assets were $27.2 million against total liabilities of $11.3 million, leaving total equity of $15.8 million. The company reported no material unsecured debt.

Analysis — what it means for markets and sectors

NextPlat sits at the intersection of two distinct exposures: US community pharmacy economics and global satellite connectivity retail. The pharmacy side carries reimbursement-rate risk; the e-commerce side carries demand risk tied to hardware and airtime subscriptions.

The 340B contracted-services growth is the most defensible part of the quarter, because contract revenue is less exposed to the reimbursement compression that shrank retail prescription revenue. If the newly signed contracts onboard as planned, they should convert into revenue in early 2027, though the company has not disclosed contract values or terms.

The counter-argument is scale. At roughly $10.5 million in quarterly revenue, NextPlat remains a small-cap operator whose margin gains rest on a narrow set of contracts and a pharmacy network concentrated in Florida. A single lost 340B relationship or a further reimbursement cut would move the numbers materially.

Positioning is likely to hinge on whether investors treat the margin improvement as durable or as a one-off mix effect. The company carries no material unsecured debt and roughly $13.5 million in working capital, which limits near-term financing pressure but also caps how aggressively it can fund acquisitions without dilution.

For the broader pharmacy sector, the quarter is a reminder that reported revenue growth and profitability can move in opposite directions when reimbursement rates reset. Any operator with heavy retail prescription exposure faces the same arithmetic.

Outlook — what to watch next

The company expects retail prescription volumes to rise starting in the fourth quarter as it begins recognizing contributions from its recently acquired Pensacola-area Scott's pharmacy and its new Jacksonville location. The Scott's acquisition closed immediately after the quarter ended, and NextPlat said Scott's gross margins have already improved.

A nationwide medication fulfillment website is slated to launch in the fourth quarter, covering all 50 US states. The company said the platform is intended to extend PharmcoRx beyond Florida and create a scalable national e-commerce channel. No launch date within the quarter was given.

On the e-commerce side, NextPlat expects to add more international marketplaces during the fourth quarter after opening a channel with Decathlon, which is selling satellite connectivity products to online customers in 20 countries.

The company also said it continues to explore selective acquisitions that could increase pharmacy network scale, including potentially outside Florida. Management named automated dispensing as a planned new service. Investors should watch whether the new 340B contracts begin contributing revenue before the first half of 2027.

Frequently Asked Questions

Why did NextPlat's revenue fall while its gross margin rose?

Lower reimbursement rates and fewer retail prescriptions cut prescription revenue to about $4.3 million from roughly $9.5 million. Those same prescriptions carried thin margins, so removing them lifted consolidated gross margin to about 35.0% from 19.9%. Higher-margin contracted 340B pharmacy services partially offset the revenue decline, rising 300% to about $2.4 million.

What is NextPlat's 340B business and why does it matter?

340B refers to a US federal program allowing qualifying hospitals and clinics to buy outpatient drugs at reduced prices. NextPlat provides contracted pharmacy services to those entities. The company said 340B prescription volumes grew nearly 72% year-over-year and it added three new 340B contracts during the quarter, with onboarding underway and revenue expected in early 2027.

How much cash does NextPlat have and is it burning it?

NextPlat ended the quarter with approximately $11.2 million in cash and $13.5 million in working capital, against no material unsecured debt. Cash declined from $13.7 million at December 31, 2025, while receivables and inventory both increased. The company did not disclose a cash burn rate or runway estimate in the report.

Bottom Line

NextPlat traded $3.3 million of quarterly revenue for a 15-point margin gain and a two-thirds smaller net loss.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.